The results from the current network meta-analysis are also consistent with the established efficacy of SGLT2 inhibitors for improving cardiovascular outcomes in conditions other than diabetes (such as heart failure or chronic kidney disease), which are not characterized by hyperglycemia. This evidence concerns the gene SLC5A2 and heart failure.